Evidence map›Paper›PMID 35868253›Full record

ArticleMolecular cell2022

A tRF nucleator for Nucleolin in cancer metastasis.

Yichen Xu, Davide Ruggero

Abstract readComment
PubMed Publisher
In one paragraph

Article in Molecular cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Disruption of the Nucleolin-CXCR4 interaction by the DNA aptamer HY-4 halts colorectal cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Yichen XuCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China; Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China.
Davide RuggeroDepartment of Urology, University of California San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA. Electronic address: davide.ruggero@ucsf.edu.
Second Affiliated Hospital of Zhejiang University · CNUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

Mechanisms of regulated translation control in cancer and its therapeutic implicationsR35CA242986 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUGGERO, DAVIDE · 2019 to 2025
$6.4M
ERa is a novel RNA-binding protein controlling breast cancerR01CA271437 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Davide Ruggero · 2022 to 2026
$2.3M
NCI NIH HHS R01 CA271437NCI NIH HHS R35 CA242986
6 · The paper itself

Abstract

In this issue of Molecular Cell, Liu et al. (2022) report that 5'-tRF

Indexed as

Breast NeoplasmsRNA-Binding ProteinsFemaleHumansNucleolinPhosphoproteinsRNA, TransferNucleolinPhosphoproteinsRNA-Binding ProteinsRNA, Transfer

Identifiers

PMID35868253
OpenAlexW4286449422

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.